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Background: Oral squamous cell carcinoma (OSCC) has a remarkably high incidence worldwide, and a fairly serious
prognosis, encouraging further research into advanced technologies for noninvasive methods of making early
diagnoses, ideally in primary care settings.
Objectives: Our purpose was to examine the validity of using advanced noninvasive technologies in diagnosis of
OSCC by identifying and evaluating relevant published reports.
Data source: MEDLINE, EMBASE, and CINAHL were searched to identify clinical trials and other information
published between 1990 and 10 June 2014; the searches of MEDLINE and EMBASE were updated to November
2014. Study selection: Studies of noninvasive methods of diagnosing OSCC, including oral brush biopsy, optical
biopsy, saliva-based oral cancer diagnosis, and others were included.
Data extraction: Data were abstracted and evaluated in duplicate for possible relevance on two occasions at an
interval of 2 months before being included or excluded.
Data synthesis: This study identified 163 studies of noninvasive methods for diagnosing OSCC that met the
inclusion criteria. These included six studies of oral brush biopsy, 42 of saliva-based oral diagnosis, and 115 of optical
biopsy. Sixty nine of these studies were assessed by the modified version of the QUADAS instrument. Saliva-based
oral cancer diagnosis and optical biopsy were found to be promising noninvasive methods for diagnosing OSCC.
Limitation: The strength of evidence was rated low for accuracy outcomes because the studies did not report
important details required to assess the risk for bias.
Conclusions: It is clear that screening for and early detection of cancer and pre-cancerous lesions have the potential
to reduce the morbidity and mortality of this disease. Advances in technologies for saliva-based oral diagnosis and
optical biopsy are promising pathways for the future development of more effective noninvasive methods for
diagnosing OSCC that are easy to perform clinically in primary care settings.
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Oral cancer is the eighth most common cancer world-
wide and represents a significant disease burden. If de-
tected at an early stage, survival from oral cancer is
better than 90% at 5 years, whereas survival of patients
presenting with late stage disease is only 30%. The 5-
year survival rate for oral cancer has remained less thanCorrespondence: esamomar@hotmail.com
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unless otherwise stated.50% over the last 50 years for the following reasons
[1,2]: (i) most oral cancers (60%) are diagnosed at ad-
vanced stages (III and IV); and (ii)) oral cancer is subject
to the “field cancerisation phenomenon”, having the
highest risk of development of second primary tumours
of any cancer.
Although the precise sequence and number of events
required for tumourigenesis remains unknown, under-
standing of tumourigenesis may help in development of
more effective methods for diagnosis and treatment. A
recent series of experiments performed by Hahn et al.an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that the following six important steps are likely neces-
sary for a cancer to develop [3-5]: (i) acquisition of
autonomous proliferative signalling; (ii) inhibition of
growth inhibitory signals; (iii) evasion of programmed
cell death; (iv) immortalisation; (v) acquisition of a nu-
trient blood supply (angiogenesis); and (vi) acquisition
of the ability to invade tissue.
Accounting for 96% of all oral cancers, squamous cell
carcinoma (SCC) is usually preceded by dysplasia pre-
senting as white epithelial lesions on the oral mucosa
(leukoplakia). Leukoplakias develop in 1–4% of the
population [6]. Malignant transformation, which is quite
unpredictable, develops in 1–40% of leukoplakias over
5 years [6]. Dysplastic lesions in the form of erythropla-
kia (red lesions) carry a 90% risk of malignant conver-
sion [6]. Tumour detection is further complicated by a
tendency towards field cancerisation, leading to multi-
centric lesions, all of which may not be clinically visible
[7]. These benign lesions are often biopsied surgically; in
most cases multiple follow-up biopsies are indicated.
The following disadvantages of surgical biopsies can dis-
courage patients from agreeing to further diagnostic bi-
opsies: (i) fear and stress; (ii) pain and damage to healthy
tissue; (iii) risk of infection; (iv) temporary disability and
discomfort; and (v) cosmetic concerns.
The peak incidence of oral squamous cell carcinoma
(OSCC) is between the ages of 45 and 75 years. The in-
creasing number of older persons worldwide, together
with concomitant increases in the incidence of malig-
nancies, are creating a pressure on healthcare systems
[8]. The percentage of people aged over 65 years will
grow substantially between 2010 and 2030, the predicted
annual growth rate being 2.8% (EURON, 2004). Health-
care is expected to become increasingly inadequate over
the coming years. If reliance is placed on current con-
ventional diagnostic technologies, which are subjective
and depend on examiner experience, provision of suffi-
cient quality and quantity of these would place further
demands on the availability of healthcare [8]. There is a
thus a strong need to develop new, objective, noninva-
sive methods for diagnosing OSCC that can be per-
formed by primary care providers: these would improve
the outcome of this disease and minimise strain on spe-
ciality referral centres. Minimally invasive interventions
are critical to improving healthcare efficiency, enhancing
the quality of care provided, and reducing cost. The
trend is toward facilitating the making of early diagnoses
of OSCC by GPs or dentists possible in primary care set-
tings. The major advantages of these techniques compar-
ing with conventional surgical biopsy are [8]: (i) reduced
fear and stress; (ii) reduced pain and damage to healthy
tissue; (iii) reduced risk of infection; (iv) shorter recovery
times and quicker return to work; (v) very ill patientscan also be investigated and treated; (vi) more cosmetic-
ally pleasing outcomes; and finally (vii) improved cost-
effectiveness of diagnostic procedures (polyclinic).
Minimally invasive intervention is considered one of
the most important developments in the healthcare in-
dustry. The global market for minimally invasive inter-
vention is steadily growing, its annual growth rate being
approximately 10% [8]. As patients become more aware
of the rapid technological advances, they demand less
invasive procedures [8].
In 1986, Bouquot noted that as many as 10% of US
adults have some form of oral abnormality that requires
histopathological assessment [9]. One of the oldest non-
invasive techniques is application of toluidine blue (TB),
which has an affinity for nucleic acids and therefore
binds to nuclear material in tissues with a high DNA
and RNA content [9-11]. However, because it is highly
subjective, inexperienced practitioners cannot use this
technique to diagnose OSCC. A reliable method for
diagnosing oral mucosal abnormalities has been and re-
mains the scalpel biopsy. Because most patients are fear-
ful and stressed about the prospect of scalpel biopsies,
oral brush biopsy has been developed as a less invasive
substitute [9-11]. For decades, dental healthcare profes-
sionals have measured the buffering capacity and bacter-
ial content of saliva to assess the risk of developing
tooth decay. Today, scientific and technological advances
in biochemistry, microbiology, and immunology are
leading to the discovery of new biomarkers in saliva that
can be used to detect systemic illnesses such as ischemic
heart disease, heart failure, and cancer [12-18]. Saliva
diagnosis received a major boost in 2002 when the US
National Institute of Dental & Craniofacial Research
funded a project under the title of “Development and
validation technologies for saliva-based diagnostics”.
This project has created a collaborative team of engi-
neers, experts in nanotechnology and biomedical diag-
nostic fluids, and scientists in oral biology to develop a
point-of-care technique that is automated, miniaturised
and has a multiplexed platform (lab-on-a-chip) [12,13].
The saliva-based diagnoses are a new noninvasive path-
way for diagnosing OSCC in the future with develop-
ment of point of care.
Optical biopsy involves light–tissue interactions and
different types of spectroscopy depending on the nature
of the tissues and type of excitation light used [14-18].
The development of optical techniques for noninvasive
diagnosis of OSCC is an ongoing challenge in biomed-
ical optics. Optical diagnostics have provided a reliable
objective resource that can be used to give instant diag-
noses of soft and hard tissue diseases. Multiple studies
have suggested that different technologies of optical bi-
opsy are almost as accurate as surgical biopsy. Most of
the experimental spectroscopy work in head and neck
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Raman spectroscopy, elastic scattering spectroscopy
(ESS), optical coherence tomography (OCT), and micro-
endoscopy (for the upper aerodigestive tract) [14-18].
Despite significant advances in cancer treatment, early
detection of cancer and its curable precursors remains
the best way of optimising patient survival and quality of
life. The most common noninvasive methods for diag-
nosing OSCC are summarised in List 1.
List 1 Summary of the most common non-invasive
methods for diagnosing oral squamous cell carcinoma
 Toluidine blue
 Oral brush biopsy– Conventional oral brush biopsy
– Oral brush biopsy coupled with computer-
assisted analysis




 Light-based detection systems:
– Chemiluminescence (ViziLite Plus; Microlux/DL,
Orascoptic-DK)
– Tissue fluorescence imaging (VELscope)
 Optical Biopsy:
– Tissue fluorescence spectroscopy
– Raman spectroscopy
– Elastic scattering Spectroscopy
– Differential path-length spectroscopy
– Nuclear magnetic resonance spectroscopy
– Confocal reflectance microscopy (CRM)
– Optical Coherence Tomography





 Laser capture microdissection
Methods
This systematic review studied noninvasive methods for
diagnosing OSCC.
Key questions
This study was designed to answer the following four
key questions.
1) Why is TB staining unreliable?
2) What is the sensitivity and specificity of oral brush
biopsy?
3) How does the accuracy of different types of optical
biopsy compare with that of surgical biopsy for
diagnosis of OSCC?4) What changes may develop in oral saliva in OSCC
patients and those who are at high risk of OSCC
and are these changes diagnostic for OSCC?
Data sources and selection of articles for possible
inclusion
Exception for one study from 1986, MEDLINE, EMBASE,
the Cochrane Library, and CINAHL were searched to
identify clinical trials and other information published be-
tween 1990 and 10 June 2014; the searches of MEDLINE
and EMBASE were updated to November 2014. The major
terms and concepts searched included (but were not lim-
ited to) the following: surgical biopsy, optical biopsy, saliva-
based oral cancer diagnosis, and saliva changes in people
with cancer. Table 1 provides a complete list of search
terms and strategies.
The fundamental a priori criteria for inclusion of studies
were that they involved direct comparison of a noninvasive
method with surgical biopsy; 10 or more patients were en-
rolled for the purpose of making a primary diagnosis of an
oral mucosal abnormality; and the findings were published
as an English-language, full-length, peer-reviewed article.
List 2 shows all of the study inclusion criteria.
List 2 Inclusion criteria
1 Studies addressing Key Questions 1 and/or 2
2 Studies prospective in design
3 Enrollment of 10 or more patients for the purpose
of diagnosis
4 The patients assessed by the gold standard
(surgical biopsy)
5 Non-invasive methods in diagnosis of OSCC– Toluidine blue staining,





– Elastic scattering spectroscopy,
– Differential path-length spectroscopy,
– Optical Tomography
– Nuclear magnetic resonance spectroscopy
7 Auto-fluorescence spectroscopy,
– Enhanced dye fluorescence,
– Ratio imaging
8 Saliva:
– Saliva-based oral cancer diagnosis







Table 1 A complete list of search terms and strategies
Set Concept Search statement
1 Oral Oral cavity
2 Oral biopsy Surgical biopsy, Toluidine blue staining, Oral brush biopsy, Optical Biopsy
3 Optical Biopsy Fluorescence spectroscopy, Raman spectroscopy, Elastic scattering spectroscopy,
Differential path-length spectroscopy, Optical Tomography
4 Fluorescence spectroscopy Auto-fluorescence spectroscopy, Enhanced dye fluorescence, Ratio imaging
5 Oral diseases Tumors, carcinoma
6 Combined set 2, 5
7 Combined set 3, 5
8 Combined set 3, 4, 5
9 Saliva Saliva-based oral cancer diagnosis,
10 Oral Saliva changes in cancer patients Genomic substance, Transcriptomic mRNA, Proteomic substances
11 Combined set 9, 10
12 Combined set 6, 7, 8, 11
13 Limit by publication type 5,6, 8, 11, 12: Not letter or editorial or news or comments or case report or notes
or conference paper
14 Diagnostics filter 13 and (predictive value of tests or sensitivity and specificity or accuracy or
diagnostic accuracy or precision or likelihood) or (false or true) or
(positive or negative)
15 Clinical trials filter 14 and (Randomized controlled trials or random allocation or double-blind method
or single-blind method or cross-over studies or crossover procedure or double
blind procedure or single blind procedure or crossover design or double-blind
studies or single-blind studies or triple-blind studies or random assignment or
exp controlled study/or exp clinical trial/or exp comparative study or intermethod
comparison or parallel design or control group or prospective study or case control
study or major clinical study) or Case control studies/or Cohort/or Longitudinal
studies/or Evaluation studies/or Prospective studies
16 Combined set 14, 15
17 Patient satisfaction 13 and (patient satisfaction or pain measurement or pain assessment or visual analog
scale or quality of life).
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evaluated in duplicate for possible relevance on two oc-
casions at intervals of 2 months; 313 abstracts were thus
identified. When exclusion and inclusion criteria were
applied at the abstract level, 62 abstracts were excluded.
The 286 full-length articles of studies that seemed rele-
vant at the abstract level were then obtained and the full
articles examined to ascertain whether they met the in-
clusion criteria; 194 of these articles met the inclusion
criteria (Figure 1).
Data abstraction and quality assessment
Standardised data abstraction forms were created, the
relevant data abstracted from each article, and the accur-
acy of the abstracted data verified. A modified version of
the Quality Assessment of Diagnostic Accuracy Studies
(QUADAS) instrument developed by Whiting et al. was
used to assess the internal validity of each of the in-
cluded studies because we considered the original form
of QUADAS adequate (List 3) [19]. The modificationsmade to this instrument included the following: (i) were
the patients assessed by the gold standard? (surgical
biopsy); (ii) were the patients assessed by a reference
standard regardless of the biopsy results?; (iii) was fund-
ing for this study provided by a source with no obvious
financial interest in the findings?; (iv) was the design
prospective?; (v) were complete data reported?; (vi) were
all patients assessed by the reference standard?; (vii)
were interreader differences accounted for?; and (viii)
were readers and outcome assessors blinded? List 4 pro-
vides the full list of items modified.
List 3 (Modified Diagnostic Accuracy Studies
(QUADAS) instrument developed by Whiting et al.)
Category 1: Spectrum composition
Was the spectrum of patients described in
the paper and was it chosen adequately?
Were selection criteria described clearly?
Was the method of population recruitment
consecutive?
Figure 1 PRISMA diagram.
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Was disease prevalence and severity reported?
(not included in QUADAS)
Category 2a: Index test and reference standard:
Selection and execution
In light of current technology, was the reference
standard chosen appropriate to verify test results?
Is it possible that a change in the technology of the
index test has occurred since this paper was
published? (not included in QUADAS)
Was there an abnormally long time period between
the performance of the test under evaluation and the
confirmation of the diagnosis with the reference
standard?
Was the execution of the index test described in
sufficient detail to permit replication of the test?Was the execution of the reference standard
described in sufficient detail to permit replication of
the test?
Did the whole sample, or a random selection of the
sample, receive verification using a reference
standard of diagnosis?
Did all patients receive the same reference standard
regardless of the index test result?
Were the results of the index test incorporated in the
results of the reference standard?
Was the cut-off value pre-specified or acceptable in
light of previous research? (not included in
QUADAS)
Was treatment started based on the knowledge of the
index test results before the reference standard was
applied? (not included in QUADAS)
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Interpretation
Were the index test results interpreted blind to the
results of the reference standard?
Were the reference standard results interpreted blind
to the results of the index test?
Was clinical data available when test results were
interpreted?
Is data presented on observer or instrument variation
that could have affected the estimates of test
performance? (not included in QUADAS)
Category 3: Analysis
Were appropriate results presented (sensitivity,
specificity, likelihood ratios, diagnostic odds ratios,
predictive values) and were these calculated
appropriately? (not included in QUADAS)
Was a measure of precision of the results presented
(confidence intervals, standard errors)? (not included
in QUADAS)
Were uninterpretable/indeterminate/ intermediate
results reported and included in the results?
Was the threshold value specified retrospectively
based on analysis of the results? (not included in
QUADAS)
Were reasons for drop-out from the study reported?
Were subgroup analyses pre-specified and clinically
relevant? (not included in QUADAS)
Were results presented in a 2 × 2 data table? (not
included in QUADAS)
Was any indication of the utility of the test provided?
(not included in QUADAS)
Category 4: Research Planning
Was an appropriate sample size calculation
performed and were sufficient patients included in
the study? (not included in QUADAS)
Were study objectives clearly reported? (not included
in QUADAS)
Was there any evidence that a study protocol had
been developed before the study was started? (not
included in QUADAS)
List 4 Quality assessment instrument (the full list of
items modified)
1 Was the study prospective in design?
2 Were the patients assessed by the gold standard
(surgical biopsy)
3 Were patients assessed by a reference standard
regardless of the biopsy results
4 Was funding for this study provided by a source that
doesn’t have an obvious financial interest in the
findings of the study
5 Did the study account for inter-reader/scorer
differences?6 Were the reader(s) of the investigated procedure
blinded to the results of the reference standard?
7 Were readers of the reference standard blinded to
the results of the study?
8 Were the readers of the investigated procedure
blinded to all other clinical information?
9 Were readers of the reference standard blinded to all
other clinical information?
10 The experience of the investigation’s team in the
relevant field
The strength of evidence supporting each major conclu-
sion was graded as high, moderate, low, or insufficient.
According to the modified version of the QUADAS in-
strument, the proportion of tools covering each item were
classified as follows: Grade I, 75–100%; Grade II, 50–74%;
Grade III, 25–49%; and Grade IV, 0–24% [19]. Studies
classified as Grades III and IV were excluded; thus, only
prospective studies have been were included in this
assessment.
Statistical analysis
Statistical analysis was performed using Microsoft office
XL version 2007, which was used to calculate the 30 var-
iables in the modified version of QUADAS [19]. The
items were scored by using the terms used in QUADAS,
namely, Yes, No, and Unclear. The “Yes” answer was
given two points, “No” no points, and “Unclear” one
point. The total number of points was divided by six to
obtain a score over 10.
Results
Evidence of validity of non-invasive methods in
diagnosing OSCC
This study identified 163 studies of noninvasive methods
for diagnosing OSCC that met the inclusion criteria.
These included six studies of oral brush biopsy, 42 of
saliva-based oral diagnosis, and 115 of optical biopsy.
Sixty nine of these studies were assessed by the modified
version of the QUADAS instrument [19] (Table 2).
Selected important study quality items
These 5 study quality measures have been judged as
highly important for reducing the risk for bias when ad-
dressing the key questions of this review. “Reported suf-
ficient relevant clinical information” refers to whether
the study reported clear and sufficient information about
the study design, patient inclusion and exclusion criteria
and characteristics and biopsy methods to fully address
the key questions and fully assess the potential for bias
in the study design. “Index test results blinded” refers to
whether readers were aware of the reference standard of
biopsy results. “Differential verification bias avoided” re-
fers to whether the reference standard was chosen
Table 2 Analysis of studies addressing key questions 1, 2, 3 or 4 that met the inclusion criteria








Funded by Number of
patients enrolled
Epstein et al. 1997 [10] Toluidine blue 7 Prospective Department of Dentistry, British Columbia
Cancer Agency
Canada British Columbia Cancer Agency -
Bouquot et al. 1986 [11] Toluidine blue 6.5 Prospective - USA - 23,616
Martin et al. 1998 [23] Toluidine blue 6.3 - Department of Oral and Facial Surgery,
Sunderland Royal Hospital
UK - -
Scheifele et al. 2004 [24] OralCDx®
technique
6.4 Prospective Department of Oral Surgery and Dental




Sciubba 1999 [26] OralCDx®
technique
7.3 Prospective Department of Dental Medicine, Long Island
Jewish Medical Center
USA U.S. Collaborative OralCDx®
Study Group
945
Gupta et al. 2007 [26] Oral brush
biopsy
5.8 Prospective Department of Pathology, Moti Lal Nehru
Medical College, Allahabad University
India - 96
Poate et al. 2004 [28] Oral brush
biopsy
7.5 Prospective Oral Medicine, Division of Maxillofacial
Diagnostic, Medical and Surgical Sciences,
Eastman Dental Institute for Oral Health
Care Sciences
UK - 112
Weigum et al. 2010 [29] Nanobiochip,
exfoliative
cytology
7.7 Prospective Department of Dental Diagnostic Science,
University of Texas Health Science Center
USA National Institute for Dental
and Craniofacial Research
52
Jokerst et al. 2010 [31] Nanobiochip 6.6 Prospective Stanford University School of Medicine USA - -
Wei et al. 2009 [32] Saliva
biomarkers
7.5 Prospective University of California, Los Angeles School
of Dentistry and Dental Research Institute
USA NIH/National Institute of Dental
and Craniofacial Research
-
Floriano et al. 2009 [33] Saliva-based
nanobiochip
tests
7.6 Prospective Department of Chemistry and Biochemistry,
University of Texas
USA National Institute of Dental and
Craniofacial Research
41
Liu et al. 2009 [34] Saliva
biomarkers
7.5 Prospective Department of Mechanical Engineering
and Applied Mechanics,
USA University of Pennsylvania Institute
for Translational Medicine and
Therapeutics
-
Zimmermann et al. 2007 [36] Saliva
biomarkers
7.8 Prospective School of Dentistry and Dental Research
Institute, University of California
USA National Institute of Health -
Xie et al. 2008 [37] Saliva
biomarkers
7 Prospective Department of Biochemistry, Molecular
Biology, and Biophysics, School of Dentistry,
University of Minnesota
USA - -
Sugimoto et al. 2010 [39] Saliva
biomarkers
8 Prospective UCLA Medical Center USA National Institute of Health 215
Hu et al. 2008 [41] Saliva
biomarkers
7.6 Prospective Oral Biology and Medicine Division and
Dental Research Institute, School of
Dentistry, University of California
USA U.S. Public Health Service 64
Rosin et al. 2000 [44] Biomarkers;
genetic
7.7 Prospective British Columbia Cancer Agency/Cancer
Research Centre
Canada National Cancer Institute of
















Table 2 Analysis of studies addressing key questions 1, 2, 3 or 4 that met the inclusion criteria (Continued)
Boyle et al. 1993 [48] Biomarkers;
genetic
7.6 Prospective Department of Oral Surgery, Johns
Hopkins University
USA - 102
Rosas et al. 2001 [50] Biomarkers;
genetic
7.9 Prospective Department of Otolaryngology, Head
and Neck Surgery, Johns Hopkins University
School of Medicine
USA National Institute of Dental and
Craniofacial Research (NIH)
30
Chien et al. 1990 [52] Biomarkers;
genetic
7.5 Prospective Department of Obstetrics and Gynaecology,
First Affiliated Hospital, Human Medical
University
China - 92
Handschel et al. 2007 [54] Biomarkers;
genetic
6.9 Prospective Department for Cranio- and Maxillofacial
Surgery, Heinrich-Heine-University
Germany - -
Hasselmann et al. 2001 [55] Saliva
biomarkers;
clinical chemistry
6.4 Prospective Department of Dermatology, Saarland
University Hospital
Germany - -
Ratajczak et al. 2006 [56] Biomarkers;
cellular
7.2 Prospective James Graham Brown Cancer Center,
University of Louisville
USA Stem Cell Biology Program -
García et al. 2008 [57] Biomarkers;
genetic
7.5 Prospective Department of Medical Oncology, Hospital
Universitario Puerta de Hierro
Spain Ministerio de Educación y Ciencia and
the Fundación de Investigación
Médica Mutua Madrileña
-
Skog et al. 2008 [59] Biomarkers;
genetic
7.5 Prospective Department of Neurology, Massachusetts
General Hospital, and Neuroscience
Program, Harvard Medical School
USA Wenner-Gren Foundation Stiftelsen
Olle Engkvist Byggmästare, Brain
Tumor Society, and American Brain
Tumor Association
-
Shpitzer et al. 2009 [63] Saliva
biomarkers
7.8 Prospective Department of Otorhinolaryngology, Rabin
Medical Center, Petah Tiqva and Sackler
Faculty of Medicine
- - 19
Vairaktaris et al. 2008 [64] Saliva
biomarkers
7.5 Prospective Department of Oral and Maxillofacial
Surgery, University of Athens Medical
School, Attikon Hospital
Greece - 152
St John et al. 2004 [64] Saliva
biomarkers
7.7 Prospective School of Medicine, UCLA USA National Institutes of Health, UCLA
Jonsson Cancer Center
32
Rhodus et al. 2005 [66] Saliva
biomarkers
7.6 Prospective Department of Oral Medicine, University
of Minnesota
USA - 13
Arellano-Garcia et al. 2008 [67] Saliva
biomarkers
7.5 Prospective School of Dentistry, Oral Biology and
Medicine Division, Dental Research
Institute, University of California
USA U.S. Public Health Service 19
Betz et al. 2002 [111] Optical biopsy 7.9 Prospective Department of Oto-Rhino-Laryngology/
Head and Neck Surgery, Ludwig Maximilians
University
Germany Wilhelm Sander Foundation 85
Leunig et al. 2000 [112] Optical biopsy 7.5 Prospective Department of Otorhinolaryngology–
Head and Neck Surgery, University of Munich
Germany Wilhelm Sander Foundation 8
Betz et al. 1999 [101] Optical biopsy 7.7 Prospective Department of Oto-Rhino-Laryngology/Head
& Neck Surgery, Ludwig Maximilian University















Table 2 Analysis of studies addressing key questions 1, 2, 3 or 4 that met the inclusion criteria (Continued)
Kulbersh et al. 2007 [103] Optical biopsy 7.5 Prospective Department of Surgery, Division of
Otolaryngology-Head and Neck Surgery,
University of Alabama
USA American Cancer Society, University of
Alabama at Birmingham
Comprehensive Cancer Center Core
Grant NIH
33 Models
Ebenezar et al. 2012 [113] Optical biopsy 7.3 Prospective Anna University, Department of Medical Physics India - 25
Duraipandian et al. 2012 [118] Optical biopsy 7.8 Prospective National University of Singapore, Department
of Bioengineering, Faculty of Engineering,
Optical Bioimaging Laboratory
Singapore National University of Singapore 2748
Guze et al. 2014 [133] Optical biopsy 7.8 Prospective Department of Oral Medicine, Infection and
Immunity, Harvard School of Dental Medicine,
Divisions of Oral Medicine, Dana-Farber
Cancer Institute and Brigham and Women’s
Hospital
USA - 18
Krishnakumar et al. 2013 [125] Optical biopsy 7.5 Prospective Department of Physics, Annamalai University India - -
Sahu et al. 2013 [126] Optical biopsy 7 - Chilakapati lab, ACTREC, Tata Memorial Centre India Advanced Centre for Treatment
Research and Education in Cancer
70
Singh et al. 2013 [128] Optical biopsy 7.3 Prospective Chilakapati lab, ACTREC, Tata Memorial Centre India Advanced Centre for Treatment
Research and Education in Cancer
84
Singh et al. 2012 [127] Optical biopsy 7.5 Prospective Advanced Centre for Treatment Research
and Education in Cancer, Chilakapati Laboratory
India Advanced Centre for Treatment
Research and Education in Cancer
104 subjects
Deshmukh et al. 2011 [129] Optical biopsy 7 Prospective Chilakapati Laboratory India Advanced Center for Treatment
Research and Education in Cancer
10
Oliveira et al. 2006 [130] Optical biopsy 7.2 Prospective Grupo de Optica Biomédica, Instituto de
Pesquisa e Desenvolvimento, Universidade
do Vale do Paraíba
Brazil - 123 spectra
Malini et al. 2006 [131] Optical biopsy 7.5 Prospective Center for Laser Spectroscopy, Manipal
Academy of Higher Education
India Government of India 216 spectra
Krishna et al. 2004 [132] Optical biopsy 6.8 Prospective Center for Laser Spectroscopy, Manipal
Academy of Higher Education
India Government of India -
Jerjes et al. 2004 [135] Optical biopsy 7.5 Prospective Department of Oral and Maxillofacial Surgery,
University College London Hospitals
UK Eastman Dental Institute, UCL, UCLH
Head and Neck Centre
13
Sharwani et al. 2006 [140] Optical biopsy 7.6 Prospective Oral and Maxillofacial Surgery, Eastman
Dental Institute
UK Eastman Dental Institute, UCL, UCLH
Head and Neck Centre, London, UK
25
Mourant et al. 2000 [137] Optical biopsy 7 Prospective Los Alamos National Laboratory, Bioscience
Division
USA - -
Mourant et al. 1998 [138] Optical biopsy 7.2 Prospective Chemical Sciences and Technology Division,
Los Alamos National Laboratory
USA - -
Lovat et al. 2006 [139] Optical biopsy 7.8 Prospective National Medical Laser Centre, Department
of Surgery, Royal Free and University College
Medical School, University College
UK National Cancer Institute 181

















Table 2 Analysis of studies addressing key questions 1, 2, 3 or 4 that met the inclusion criteria (Continued)
Denkçeken et al. 2013 [145] Optical biopsy 6.9 Prospective Biomedical Optics Research Unit, Department
of Biophysics, Faculty of Medicine, Akdeniz
University
Turkey Biomedical Optics Research Unit 10
Qi et al. 2012 [143] Optical biopsy 7.7 Prospective Department of Surgery and Cancer, Imperial
College London
UK ERC grant (China Scholarship Council) -
Upile et al. 2012 [142] Optical biopsy 7.8 Prospective Head & Neck Unit, University College London
Hospitals
UK Eastman Dental Institute, UCL, UCLH
Head and Neck Centre
73
Canpolat et al. 2012 [141] Optical biopsy 7.6 Prospective Department of Biophysics, School of Medicine,
Akdeniz University
Turkey - 28
Lau et al. 2009 [146] Optical biopsy 7.9 Prospective Massachusetts Institute of Technology,
George R. Harrison Spectroscopy Laboratory
USA National Institutes of Health -
Müller et al. 2003 [136] Optical biopsy 7.9 Prospective Massachusetts Institute of Technology USA National Institutes of Health 91 tissue sites
from 15 patients




Dutch Technology Foundation STW,
Applied Science Division of NWO and
the Technology Program of the
Ministry of Economic Affairs
-
Sterenborg et al. 2009 [148] Study type(s) or
biopsy




Dutch Technology Foundation STW,
Applied Science Division of NWO and
the Technology Program of the
Ministry of Economic Affairs
21
de Visscher et al. 2012 [150] Study type(s) or
biopsy
7.5 Prospective University Medical Centre Groningen,




Dutch Technology Foundation STW,
Applied Science Division of NWO and
the Technology Program of the
Ministry of Economic Affairs
54 male Wistar
rats
Amelink et al. 2011 [149] 7.7 Prospective Centre for Optical Diagnostics and Therapy,




Dutch Technology Foundation STW,
Applied Science Division of NWO and
the Technology Program of the
Ministry of Economic Affairs
18
Karakullukcu et al. 2011 [151] Study type(s) or
biopsy
7.6 Prospective The Netherlands Cancer Institute, Antoni van
Leeuwenhoek Hospital, Department of Head
and Neck Oncology and Surgery
The
Netherlands
Dutch Technology Foundation STW,
Applied Science Division of NWO and
the Technology Program of the
Ministry of Economic Affairs
-
Kanick et al. 2008 [152] Study type(s) or
biopsy
7.5 Prospective Erasmus Medical Centre, Department of




Dutch Technology Foundation STW,
Applied Science Division of NWO and
the Technology Program of the
Ministry of Economic Affairs
-
Adalsteinsson et al. 1998 [174] Study type(s) or
biopsy
7.5 Prospective Department of Radiology, Stanford University USA - 12
El-Sayed et al. 2002 [175] Study type(s) or
biopsy















Table 2 Analysis of studies addressing key questions 1, 2, 3 or 4 that met the inclusion criteria (Continued)
Maheshwari et al. 2000 [176] Study type(s) or
biopsy
7.6 Prospective Department of Radiology, University of North
Carolina
USA University of North Carolina 37
Mukherji et al. 1997 [177] Study type(s) or
biopsy
7.8 Prospective Department of Radiology, University of North
Carolina School of Medicine
USA - 49
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enrolled” refers to whether the patient’s group enrolled in
the study resembles the usual patient population seen in
clinical practice. “Avoided selection bias” refers to whether
all or consecutive patients enrolled in the study were
clearly selected by applying consistent inclusion and ex-
clusion criteria (Figure 2).
TB staining
Vital staining is the staining of living cells or tissues.
The earliest technique, developed by Paul Ehrlich in
1885, involved immersion of freshly removed tissue in
methylated blue. There are two techniques for vital
staining, namely, intravital staining within the living
body (in vivo) and supravital staining outside the body,
which usually involves preparation of slides of detached
cells [20,21]. TB is a basic thiazine metachromatic dye
with high affinity for acidic tissue components, thereby
staining tissues rich in DNA and RNA. TB staining is a
simple, inexpensive and sensitive tool for identifying
early OSCC and high-grade dysplasias [22]. A 1% aque-
ous TB solution is applied for 30 seconds, this acido-
philic metachromatic nuclear stain helps to differentiate
areas of carcinoma in situ or invasive carcinoma from
normal tissue. TB staining is highly sensitive and moder-
ately specific for malignant lesions. It has less sensitivity
for premalignant lesions, up to 58% false negatives hav-
ing been reported for identifying mild-to-moderate dys-
plasia [22,23]. Rosenberg and Cretin stated that the
sensitivity of TB staining in oral cancer screening ranges
from 93.5% to 97.8%, and the specificity from 73.3% to
92.9% [20].
Oral brush biopsy
The goal of the highly sensitive and specific technique of
oral brush biopsy is to provide a sample by a less painful
and simpler means than scalpel or punch biopsy. The
accuracy of brush tests has been the subject of many
published studies. In every study in which oral lesionsFigure 2 Study quality measures.have been simultaneously assessed by both a brush bi-
opsy and surgical biopsy, this test has been shown to
have both sensitivity and specificity well over 90%
[24,25]. Oral brush biopsy uses a circular bristled brush
that has been designed to access and sample all epithe-
lial layers, including the basal cell layer and the most
superficial aspects of the lamina propria [25]. Brush bi-
opsy has many advantages: it is a chair-side, easy to per-
form, painless test that can be used to evaluate any
suspicious lesion, including common small white and
red oral lesions, and to rule out dysplasia. Gupta et al.
combined conventional oral brush biopsy with the appli-
cation of TB to identify suspicious mucosal areas [26].
Scully et al. stated that the sensitivity of brush biopsy in
detection of dysplasia or OSCC is 71.4%, whereas the
specificity is only 32% [27]. Oral brush biopsy coupled
with computer-assisted analysis has been developed as a
technique for evaluating unexplained clinically detect-
able alterations of the surface epithelium of the oral mu-
cosa; where cancer or pre-cancer is suspected, the
sensitivity is up to 40%. [25]. This technique is based on
quantitative cytomorphometry and DNA aneuploidy
with computer-assisted analysis [25]. However, the lim-
ited specificity of current cytology-based analysis is still
a major impediment to early oral cancer detection and
intervention [24-28]. Given that exfoliative cytology also
gathers cellular DNA, RNA, and protein biomarkers,
new diagnostic techniques targeting early tumour bio-
markers and molecular transformation could enhance
the role and utility of oral cytology in clinical diagnos-
tics. Exfoliative cytology based on a nanobiochip sensor
platform for oral cancer detection was recently described
in a pilot study examining both molecular and morpho-
logical biomarkers associated with oral dysplasia and
malignancy [29]. In this study, oral epithelial cells were
captured on a membrane filter with pores smaller than
the cell size followed by immunofluorescent labelling for
the well-known epidermal growth factor receptor bio-
marker. Concurrently, the cytoplasm and nuclei were
stained with the fluorescent dyes phalloidin and 4′,6-dia-
midino-2-phenylindole, respectively, for cytomorpho-
metric measurements. The nuclear area, nuclear diameter,
nuclear/cytoplasmic ratio, and EGFR expression in malig-
nant and dysplastic oral lesions were found to differ sig-
nificantly from those in normal control epithelial cells.
This technique reportedly has 97–100% sensitivity and
86% specificity [24,28,29].
Saliva-based oral cancer diagnosis
Saliva can be considered a mirror of bodily health. The
multifarious components of saliva not only protect the
integrity of oral tissues, but also provide clues to various
local and systemic conditions and diseases. The compo-
nents of saliva are continually being explored as markers
Omar Head & Face Medicine  (2015) 11:6 Page 13 of 27of various diseases and for monitoring general health [30].
In the past few years, multiplex biomarker detection sys-
tems have emerged through remarkable progress in the
development of lab-on-a-chip and point-of-care technolo-
gies [31]. The goal of these efforts is to use developments
in nano/micro-electrical–mechanical technology to build
automated, miniaturised, and multiplexed platforms for
rapid assays and readouts. In general, the principles of
conventional enzyme-linked immunosorbent assay and/or
nucleic acid hybridisation are applied, often via either elec-
trochemical sensors [32] or microbead reactors [33,34].
The electrochemical approach uses gold electrode arrays
(multiplex chips) in which one set of electrodes (working,
counter and reference electrodes) is applied, with a cyclic
square wave electrical field to facilitate chemical reaction,
for one analyte measurement, followed by amperometric
readout [32].
Tumour cells may inhibit or produce biochemical sub-
stances referred to as tumour markers. These can be
normal endogenous products that are produced at a
greater rate in cancer cells or the products of newly
switched on genes that are quiescent in normal cells
[33-35]. Tumour markers may be present as intracellular
substances in tissues or as released substances in circu-
lating body fluids such as serum, urine, cerebrospinal
fluid, and saliva. Until recently, tumour markers were
analysed in fluids other than saliva, such as cerebro-
spinal fluid, blood, and urine. However, with recent
technological advances in diagnostic techniques, the role
of saliva as a tool for diagnosis has grown exponentially.
Saliva-based oral cancer diagnosis is a noninvasive alter-
native to serum testing and has an overall accuracy rate
of about 85%. It is an effective modality for diagnosis,
determining prognosis of oral cancer and monitoring
post-therapy status [33-35].
Relevant markers include oncogenes (e.g., C-myc, c-
Fos, C-Jun), anti-oncogenes (e.g., p53, p16), cytokines
(e.g., transforming growth factor-β1, interleukin (IL)-8,Table 3 Genomic substance
Genome Functions
Mitochondrial DNA
p53 gene: Tumor-suppressor genes Cell-cycle regulation Senescence, ce
p16* : Tumor-suppressor genes Cell-cycle regulation Senescence, ce
DAP-K* kinase whose expression is required
MGMT*
CDKN2A Control of cell cycle, arrest cell cycle
Tumor-suppressor genes
CDH1 Encodes Ca++ dependent cell to ce
c-MYCIN: Proto-oncogenes Cell growth, apoptosis
Cyclin D oncogenes: Proto-oncogenes Cell-cycle regulation
*p16, MGMT,DAP-K (methylation of at least one of these genes in 65%).and -1β), growth factors (e.g., vascular endothelial
growth factor, epidermal growth factor, and insulin-
like growth factor), extracellular matrix-degrading
proteinases (MMP1, MMP2, MMP9), hypoxia markers
(hypoxia-inducible factor-α, carbonic anhydrase-9),
epithelial-mesenchymal transition markers (e.g., E-
cadherin, N-cadherin, and β-catenin), epithelial tu-
mour factors (Cyfra 21–1), cytokeratins (CK13, 14 and
16), microRNA molecules, and hypermethylation of
cancer-related genes (p16 and death-associated protein
kinase) [36-43].
Genomic substances
Markers in the form of changes in the host DNA of dys-
plastic or cancer cells include point mutation, deletion,
translocation, amplification, and methylation (Table 3).
Loss of heterozygosity in chromosomes 3p, 9q, 13q, and
17p is considered an early event in oral carcinogenesis.
In their study, Rosin et al. [30,44] found that allelic loss
at 3p and 9q increases the risk of malignant transform-
ation by 3.8-fold; the risk further increases to 33-fold
when loss of heterozygosity occurs in chromosomes 4q,
8p, 11q, 13q and 17p in addition to the former. Mito-
chondrial DNA mutations have also been useful for de-
tecting exfoliated OSCC cells in saliva. Such mutations
have been identified in 46% of patients with head and
neck cancer [45], and have been identified by direct se-
quencing in 67% of saliva samples from OSCC patients
[45,46]. The p53 gene, which is located on chromosome
17p13.1, exhibits mutation in 50–70% of epithelial tu-
mours [47,48]. Loss of heterozygosity of the p53 allele
has been reported in 22% of cases of pre-cancer and
20% of oral cancer. Other genes related to p53 and the
cell cycle, such as p16, p27, p63, and p73 have been
found to be altered to varying degrees in oral cancer
[47,48]. Using plaque hybridisation, Boyle et al. [48]
identified tumour-specific p53 mutations in 71% of saliva
samples from patients with head and neck cancer.Type of abnormality Reported rate in
the saliva
mutations 67%
ll-cycle progression mutations 71%
ll-cycle progression Hypermethylation 47%
for IFN-γ-induced apoptosis Hypermethylation 33%
Hypermethylation 23%
at G1& G2act like a Hypermethylation 30.2%
ll adhesions Hypermethylation -
amplification 20-40%
amplification 87%
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the retinoblastoma pathway of the cell cycle, appears to be
methylated in 23–67% of primary OSCCs. CDH1 gene is
responsible for cell adhesion, promotes metastasis when
mutated, and shows promoter methylation in up to 85% of
tumours [49,50]. Rosas et al. [50] identified aberrant methy-
lation of at least one of the genes p16, O6-methylguanine-
DNA methyltransferase, or death-associated protein kinase
in OSCC and detected promoter hypermethylation in 65%
of matched saliva samples from OSCC patients. Amplifica-
tion and over-expression of c-MYCIN-MYC has been ob-
served in 20–40% of oral cancers. Das et al. [51] have
reported amplification of 11q13, which contains 1NT2,
HST1, and cyclin D oncogenes, in 30–50% of patients with
oral cancer. The specificity and positive predictive value
were higher for saliva than for serum (88.0% vs. 59.8% and
54.2% vs. 28.8%, respectively). In the case of OSCC, many
studies have noted a significant increase in salivary concen-
trations of Cyfra 21–1, tissue polypeptide-specific antigen,
and cancer antigen 125 with a sensitivity of 71%, specificity
75%, negative value 71%, and positive predictive value 75%.
On the other hand, carcinoembryonic antigen and cancer
antigen19-9 are not detected with statistically significant
frequency [51-54].
Transcriptomic mRNA
It has been speculated that salivary mRNA is contained in
apoptotic bodies [55,56] or actively released in exosomes
or microvesicles [57,58]. Researchers [59,60] have com-
pared the clinical accuracy of salivary versus blood RNA
biomarkers for oral cancer detection and found four RNA
biomarkers that have a sensitivity and specificity of 91%
and 71%, respectively, and a collective receiver operator
characteristic value of 0.95 (Table 4). A study by Speight
and Morgan found seven mRNA molecules to occur sig-
nificantly more frequently in OSCC patients than in
healthy controls [61]. These included the following: (i) IL-
8, [44,61]; (ii) IL-1β, which takes part in signal transduc-
tion, proliferation, inflammation, and apoptosis [44,61];
(iii) dual specificity phosphatase 1, which has a role in pro-
tein modification, signal transduction, and oxidative stress
[44,61]; (iv) H3 histone, family 3A, which has DNATable 4 Trascriptomic RNA
Biomarker Gene functions
DUSP1 Protein modification; signal transduction; oxidative stress
H3F3A DNA binding activity
IL1B Signal transduction; proliferation; inflammation; apoptosis
IL8 Angiogenesis; replication; calcium-mediated signaling pathw
cell adhesion; chemotaxis; cell cycle arrest; immune respons
OAZ1 Polyamine biosynthesis
S100P Protein binding; calcium ion binding
SAT Enzyme, transferase activitybinding activity [44,61]; (v) ornithine decarboxylase anti-
zyme 1, which plays a part in polyamine biosynthesis
[44,61]; (vi) S100 calcium binding protein P, which has a
role in protein binding and calcium ion binding [44,61];
and (vii) spermidine/spermine N1-acetyltransferase, which
takes part in enzyme and transferase activity [44,61].
Proteomic substances
Carbonylation signifies oxidative damage to proteins:
there is reportedly a substantial increase in salivary car-
bonyls (246%) in OSCC patients, indicating that their epi-
thelial cells are being exposed to significant free radical
attack [62]. The sensitivity and specificity for carbonyls
are 90% and 80%, respectively. MMP-9 polymorphism has
been shown to be strongly associated with increased risk
of developing OSCC [62-64]. Shpitzer et al. [63] reported
a 39% increase in MMP-9 with a sensitivity of 100% and
specificity of 79% in OSCC patients. St John et al. [65] and
Rajkumar et al. [66] found significantly increased concen-
trations of IL-6 and IL-8 in saliva of OSCC patients
(Table 5). Another study reported that patients with
OSCC have significantly higher concentrations of IL-8 in
saliva than patients with dysplastic oral lesions and normal
controls, suggesting its diagnostic value as a marker of
malignant transformation of oral premalignant lesions
[67]. Arellano-Garcia et al. [68] used Luminex xMAP
(Austin, TX, USA) technology to show that both IL-8 and
IL-1β are expressed significantly more strongly in OSCC
patients.
Light-based systems
Light-based systems depend on the assumption that ab-
sorption and reflection of light differs between normal
tissues and those with metabolic or structural changes.
Vizilite Plus with TBlue system (Zila Pharmaceuticals,
Phoenix, AR, USA), LED Dental (White Rock, BC,
Canada) Microlux/DL (AdDent, Danbury, CT, USA) and
Orascoptic DK (Orascoptic, Middleton, WI, USA) are
light-based oral cancer screening aids that have been de-
veloped with the aim of assisting identification of early
stage precancerous and cancerous lesions. LED Dental, a























phospho-Src -24 77 75
Ki67 127 58 67
Maspin -29 100 100
lactate dehydrogenase (LDH) 86 79 42
CycD1 87 100 100
Omar Head & Face Medicine  (2015) 11:6 Page 15 of 27stick, emits visible light in the 430 nm wavelength that
causes fluorescent excitation of certain compounds in
tissues. After the patients have rinsed their mouths with
acetic acid, the oral cavity is examined. With Microlux
(AdDent) and ViziLite (Zila Pharmaceuticals), the oral
cavity is examined with a battery-powered fibreoptic vis-
ible light source rather than a chemiluminescent stick;
again, prior rinsing with acetic acid is required. These
devices are not sensitive or specific for diagnosing any
type of oral lesion. Only pathologic examination of tissue
can definitively determine the biologic nature of a lesion
[68-70]. The ViziLite system offers an alternative to
white light illumination for visual examination; a dispos-
able chemiluminescent light source illuminates tissue
with blue light. Providers observe the reflected blue light
to detect abnormal changes in the oral cavity. Initial
studies conducted by Epstein et al. [69] and Kerr et al.
[70] indicated that the ViziLite potentially aids detection
of oral premalignant lesions by improving brightness
and sharpness. Epstein et al. used conventional white
light and ViziLite illumination to examine 134 patients
with oral lesions [69] and reported that two lesions were
clinically visible only under ViziLite illumination. Kerr
et al. used conventional white light followed by ViziLite
illumination to examine 501 patients with histories of
tobacco use [70] and reported that six lesions not de-
tected by conventional examination were identified by
ViziLite examination. However, other studies in which
examinations with ViziLite were performed after conven-
tional oral examinations have reported that ViziLite did
not aid in the identification of oral lesions [71-73] in 40
patients in a high prevalence population [71] or in 55
patients referred for assessment of white oral lesions
[72,73]. Because assessment by reflectance visualisation
and illumination with chemiluminescent light sources is
largely subjective and dependent on the experience of
the examiner, these are considered inappropriate tools
for primary care settings [74].Optical biopsy
Autofluorescence imaging
It has already been established that autofluorescence op-
tical biopsy can produce diagnostically useful information
about human oral cavity tissues [75,76]. Both fluorescence
imaging and fluorescence spectroscopy have been used
with encouraging results [76]. Tissue autofluorescence has
the potential to provide information about biochemical,
functional and structural transformations of fluorescent
bio-molecular complexes in vivo and has therefore been
used to investigate the molecular properties of cells and
tissue. Given that pathological transformation, therapeutic
interventions [77-90] and developmental changes [88-91]
cause biological changes in affected tissues, fluorescence
has been increasingly explored as a tool for tissue diagno-
sis and detection of malignant transformation. Moreover,
advances in light delivery and collection systems (fibreop-
tics) have facilitated the development of fluorescence-
based techniques for non- or minimally-invasive, remote
investigation of tissues using appropriate endoscopic or
catheter systems [92]. Fluorescence is an adaptable means
of achieving optical molecular contrast using diverse in-
struments including spectrophotometers, microarrays, mi-
croscopes, and endoscopes. Fluorescence measurements
can provide information not only on the specific molecu-
lar makeup of a sample but also on the local environment
of the fluorescence molecule or fluorophore. Distinct spe-
cies of fluorophores have been characterised based on
their excitation and emission spectra, quantum efficiency,
polarisation and fluorescence lifetime [78-86]. Common
endogenous fluorophores that are used to characterise tis-
sue include aromatic amino acids (tyrosine, tryptophan,
and phenylalanine), structural proteins (elastin, collagens,
and collagen cross-links), enzyme metabolic co-factors
(nicotinamide adenine [phosphate] dinucleotide [NAD{P}
H] and flavin adenine dinucleotide [FAD]), lipid compo-
nents, and porphyrins [77-90]; commercial systems are
now available for measuring autofluorescence in tissues.
For example, Xillix Technologies (Richmond, BC, Canada)
(now Novadaq Technologies, Bonita Springs, FL, USA)
[93], Storz [94], Pentax (Tokyo, Japan) [95] and Richard
Wolf (Vernon Hills, IL, USA) [96] have commercialised
endoscopic systems such as LIFE, D-light, SAFE-100,
and DAFE. These systems are equipped with fluores-
cence excitation-collection modules and have been de-
signed to analyse autofluorescence contrast to diagnose
cancers in the bronchi and gastrointestinal tract. Medi-
spectra (Lexington, MA, USA) and SpectRx (currently
Guided Therapeutics, Norcross, GA, USA) [97] have
developed devices incorporating fluorescence and reflect-
ance spectroscopy for diagnosis of cancer of the cervix.
Also, relatively recently the Food and Drug Administra-
tion (FDA) has approved a new device VELscope (LED
Dental [98]) for direct visualisation of autofluorescence in
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of 122 oral mucosa biopsies from 20 patients, Poh et al.
have shown that VELscope imaging can identify oral neo-
plasia in the operating room setting with a sensitivity of
97% and specificity of 94% [99].
Fluorescence spectroscopy
It is well known that all tissues fluoresce and that malig-
nant tissues fluoresce less than normal tissues: thus,
these tissues have different spectral characteristics. Stud-
ies have shown that when an ultraviolet or near ultravio-
let light source is used, normal oral mucosa emits more
green fluorescence than neoplastic lesions [100,101].
Malignant tissues differ from normal tissues in various
physical and chemical characteristics that are altered by
subcellular architectural changes such as nuclear grade,
nuclear to cytoplasm ratio, mitochondrial size and dens-
ity, amount of keratin, and elastin to collagen ratio. Sev-
eral mathematical methods have been proposed for
evaluating recorded spectral features of fluorochromes
and correlating these with disease states as a form of
diagnostic optical biopsy [100,101].
Autofluorescence spectroscopy
Autofluorescence imaging has recently been shown to
improve detection of premalignant and malignant oral
lesions [100,101]. This method is based on absorption of
ultraviolet and visible spectrum light by tissue fluoro-
phore molecules (NAD and hydrogen flavin adenine di-
nucleotide [100,101] [FADH] in the epithelial layer and
collagen and elastin in the stroma), which leads to emis-
sion of lower energy photons that can be detected as
fluorescence from the oral mucosa. Optical fibres may
be introduced into tissues through a hollow needle and
the tissue signals interpreted by spectrometers [100,101].
Betz et al. compared autofluorescence imaging and spec-
troscopy of normal and malignant mucosa in 49 patients
with head and neck cancer. In 13 of these patients
(43.3%), it was subjectively easier to distinguish tumours
from their surroundings by observing reduction in green
autofluorescence [102]. Spectral analysis showed con-
trasts in autofluorescence intensities between tumour
and normal tissues in 34 patients (94.4%) [102]. Mayin-
ger et al. studied endoscopic detection of oesophageal
cancer by autofluorescence spectroscopy. They obtained
129 endogenous fluorescence spectra from normal mu-
cosa and malignant lesions in nine patients with SCC
and four with adenocarcinoma of the oesophagus with a
sensitivity of 97% and specificity of 95% for diagnosis of
oesophageal carcinoma [103].
Enhanced dye fluorescence
Fluorescence can be slightly enhanced by exogenously
applying fluorescent drugs such as 5-aminolevulinic acid(5-ALA), which induces protoporphyrin IX (PPIX; an
important precursor to biologically essential prosthetic
groups such as heme, cytochrome c, and chlorophylls)
[103-107]. Recent advances include the possibility of
extracting true spectra of single fluorophores (chemical
compounds that can re-emit light upon light excitation)
by mathematically eliminating the undesired influences
of scattering and absorption. In addition, it will soon be
possible to precisely target tumour-specific enzymes
with fluorescent markers (“smart probes”), which will
improve both sensitivity and specificity [103-105]. A
study of fluorescence imaging with topical application of
5-ALA as a mouth rinse was undertaken at the Univer-
sity College London Hospitals (UCLH) Head and Neck
Centre in 71 patients who presented with clinically sus-
picious oral leukoplakia. A sensitivity of 83–90% and
specificity of 79–89% were obtained for differentiation
between normal and dysplastic lesions [108]. Several
studies at the MD Anderson Cancer Center, Houston,
Texas, reported different spectra from normal, dysplas-
tic, and malignant oral mucosa [107-112]. A University
Hospital Groningen study reported autofluorescence
spectra from 96 volunteers with no clinically observable
oral lesions. Skin colour strongly affected autofluores-
cence intensity, sex differences were found in blood ab-
sorption, and alcohol consumption was associated with
porphyrin-like peaks. However, all differences apart from
those associated with skin colour were of the same order
of magnitude as standard deviations within categories
[111]. Betz et al. [112] compared normal inspection,
combined fluorescence diagnosis and its two main com-
ponents, autofluorescence and 5-ALA-induced PPIX
fluorescence. Biopsy-controlled fluorescence imaging
and spectral analysis were performed on 85 patients with
suspected or histologically proven oral carcinoma both
before and after topical administration of 5-ALA. In
terms of tumour localisation and delimitation properties,
combined fluorescence diagnosis was clearly favourable
over either normal inspection or the two components of
combined fluorescence diagnosis. The performance of
combined fluorescence diagnosis was hindered by tumour
keratinisation but independent of tumour staging, grading,
and localisation. In spectral analysis, cancerous tissue
showed significantly greater PPIX fluorescence intensity
and less autofluorescence intensity than normal mucosa. In
this study, the reported sensitivity of enhanced dye spec-
troscopy was 100% and specificity 51% [112,113]. Leunig
et al. studied 58 patients with suspected cancer of the oral
cavity by measuring emission spectra of 5-ALA-induced
PPIX fluorescence and reported a specificity of 60% and
sensitivity of 99% after pathologic evaluation of biopsy
specimens [114]. Ebenezar et al. reported that a diagnostic
algorithm based on discriminant function scores obtained
by fluorescence excitation spectroscopy distinguished well-
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100% and specificity of 100% [115].
Ratio imaging
This technique compares a photochemical or end meta-
bolic product that is known to be increased in disease
states with another product that is known to be de-
pleted. For example, as described above, 5-ALA en-
hances PPIX, which fluoresces red after excitation with
blue light. The same excitation results in green fluores-
cence of molecules such as NAD and FADH, which are
depleted in malignant tissues with a high metabolic rate
[105-114]. Shin et al. have reported that the sensitivity of
fluorescence imaging techniques ranges from 60 to 97%
and their specificity from 75 to 99% [116].
Raman spectroscopy
The Raman effect was first discovered by Professor
Raman of Calcutta University, for which he was awarded
the Nobel prize in 1930 [117]. This effect is based on
light’s interaction with matter; when photons are di-
rected towards target matter, most pass through un-
changed. However, some photons come into contact
with molecules in the matter. Most of these photons
interact with the molecules of the substance, exciting
them to a partial quantum state, which causes emission
of photons at the same frequency as the incident photon
[118]. This process is known as elastic scattering. A
smaller number of these (approximately 1 in 106 to 1 in
108) photons undergo a process called Raman or inelas-
tic scattering, in which photons are discharged from the
material or ‘scattered’ at a differing wavelength than the
incident photon; it is this wavelength shift that is re-
corded in Raman spectroscopy [117,118].
The Raman effect occurs when light impinges on a
molecule and interacts with the electron cloud and
bonds of that molecule. In the spontaneous Raman ef-
fect, which is a form of light scattering, a photon excites
a molecule from the ground state to a virtual energy
state. When the molecule relaxes, it emits a photon and
goes into a different rotational or vibrational state. The
difference in energy between the original state and this
new state leads to a shift in the emitted photon’s fre-
quency away from the excitation wavelength [94-96,
109,110]. A laser-based spectroscopic technique for ob-
serving vibrational, rotational, and other low-frequency
modes in a system has been developed, enabling charac-
terisation of chemicals and the structure of molecules in
a sample. With this technique, laser light interacts with
molecular vibrations, phonons or other excitations in the
system, resulting in the energy of the laser photons being
shifted up or down. These shifts in energy give informa-
tion about the vibrational modes in the system. This tech-
nique delivers a vibrational spectroscopic picture of tissuecontent, thus providing immediate real-time histology
[105-107].
Raman spectroscopy is being investigated as a diagnostic
tool for characterising cancer cells and early malignant
changes and distinguishing these cells from normal cells.
It has a distinct advantage over other optical techniques: it
provides information on molecular composition and
structure of living tissue [105-107,119,120]. However, sig-
nificant problems associated with using Raman applica-
tions are that signals produced by the Raman effect are
inherently weak and Raman bands generally overlap be-
cause of various biological constituents, making it difficult
to identify individual components correctly. The strong
fluorescent background produced by biomedical samples
can completely obscure the true Raman signals. In 2000,
Raman spectroscopy was used for detection of laryngeal
malignancy [121]. Stone and colleagues examined 15 ex-
vivo biopsy specimens that had been obtained from pa-
tients of varying ages (18 to 79 years). The specimens were
allocated to one of three categories (normal, dysplastic,
and SCC). Their results demonstrated sensitivities of be-
tween 76 and 92%, depending on the tissue type exam-
ined, and specificities of over 90% [121]. In a similar study
in 2205, Lau et al. examined 47 laryngeal specimens (a
mixture of normal, papilloma, and carcinoma) by Raman
spectroscopy [122], each spectrum having a five second
acquisition time. Sensitivities were similar to those of the
study by Stone et al. (69 to 89%), with specificities ranging
from 86% to 94%. The authors determined that the ability
to discriminate between the tissue types was attributable
to spectral differences in the DNA, amino acids, collagen
and glycolipids. Lau et al. used Raman spectroscopy to
classify tissue obtained from the post-nasal spaces of six
cancer and six non-cancer patients [123]. An advantage of
utilising Raman spectroscopy in the nasopharynx is the
ability to detect submucosal tumours associated with this
cancer, preventing the need for random biopsy. Although
the study was small, differences were noted in the regions
of the spectra associated with collagen, proteins, and
lipids. Gniadecka et al. used Raman spectroscopy coupled
with neural network analysis to identify skin lesions [124].
Raman spectra were obtained from 22 samples of melan-
oma, 41 of pigmented nevi, 48 of basal cell carcinoma, 23
of seborrheic keratoses, and 89 of normal skin. These re-
searchers were able to discriminate malignant melanoma
from other disorders and normal skin based on the amide
I protein region (1660 cm-1) of the spectra with a sensitiv-
ity of 85% and specificity of 89%. In 2012, Duraipandian
et al. used Raman spectroscopy to obtain 2748 in vivo gas-
tric tissue spectra (2465 normal and 283 cancer). Based on
the randomly resampled training database (80% for learn-
ing and 20% for testing), they achieved a diagnostic accur-
acy of 85.6% (95% confidence interval [CI]: 82.9%–88.2%),
sensitivity of 80.5% (95% CI: 71.4%–89.6%) and specificity
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cer [120].
In 2009, Harris et al. [125,126] examined 40 patients
with Raman spectroscopy, 20 with an established diag-
nosis of head and neck carcinoma (not all SCC), and 20
aged-matched controls with respiratory ailments. Using
a trained genetic algorithm they reported a 75% sensitiv-
ity and 75% specificity for each cohort. When mixed
samples were used to train the algorithm, they achieved
the expected 50% sensitivity and specificity, providing
further evidence that the algorithm was able to discrim-
inate between cancer and non-cancer. The oral cavity is
readily accessible in a clinic setting and would be ideal
for the development of a Raman probe for cancer detec-
tion. Many recent studies have been used Raman spec-
troscopy for diagnosis of OSCC with reported sensitivity
of 85% and specificity of 86% [120]. Raman spectroscopy
has shown efficacy in differentiation between normal,
premalignant, and malignant tissues and can even detect
early changes such as cancer-field-effects/malignancy-
associated-changes [127-129]. Thus, oral premalignant
conditions can be objectively discriminated by Raman
spectroscopy [130,131]. However, the need for a dedi-
cated instrument and stringent laboratory conditions
limits wide screening applications of this method
[127-129]. In 2006, Oliveira et al. reported 100% sensi-
tivity and 55% specificity for near-infrared Raman spec-
troscopy for oral carcinoma diagnosis [132]. Spectral
profiles of normal, malignant, premalignant, and inflam-
matory conditions reportedly differ markedly [133-135].
Malignancy-induced biochemical changes can radically
change spectra from the epithelial region change. Major
differences between normal and malignant spectra seem
to arise from changes in protein composition and con-
formation/structure, and possibly from increased protein
content in malignant epithelia [134,135]. Guze et al. re-
ported 100% sensitivity and 77% specificity for differenti-
ating premalignant and malignant oral lesions from
normal mucosa and benign lesions in humans by Raman
spectroscopy [136].
Elastic scattering spectroscopy
ESS makes diagnoses by objective statistical and analytical
methods rather than by subjective interpretation of im-
ages. It provides optical geometrical information that is
based on white light reflectance. In ESS, photons hit tissue
and are backscattered without changes in wavelength. The
relative intensity of this backscattering is influenced by the
composition of the interrogated tissue, specifically the
relative concentration of scatterers (e.g., nuclei, mitochon-
dria, connective tissue) and absorbers (e.g., haemoglobin).
A scattering event carries with it all the characteristics of
the cellular components, which are called “scattering cen-
tres”. Pathological scattering centres may originate fromdisorganised epithelial orientation and architecture,
changes in morphology of epithelial surface thickness
and texture, cell crowding, increased distance from
subepithelial collagen layer, enlargement and hyper-
chromicity of cell nucleus, increased concentration of
metabolic organelles, and presence of abnormal protein
packages or particles [106,107,136]. The ESS method
senses micromorphology changes at the level of subcellu-
lar architectural changes, such as nuclear grade, nuclear to
cytoplasmic ratio, mitochondrial size and density, without
actually imaging the microscopic structure. Because ESS
detects changes at a subcellular level, it supplies informa-
tion that may not be provided by conventional histology.
Thus, ESS provides an optical signature of a tumour that
greatly depends on that tumour’s morphology [135-138].
The ESS system covers a range of 300–900 nm (light emit-
ted by cellular and subcellular organelles ranges from
330 nm to 850 nm) and uses a pulsed xenon arc lamp as
the light source. The system has two fibreoptic probes,
one for transmitting light into the tissue and the other for
collecting scattered light. The tip of the collecting probe is
placed in direct contact with the lesion and a background
measurement taken; the lamp is then activated. Next, an
ESS measurement is taken within 100 ms with the pulsed
lamp, after which the background spectrum is subtracted
from the ESS spectrum. The entire measurement process-
ing display takes less than 1 second [104-106]. In sum-
mary, ESS provides a point measurement that uses
appropriate optical geometry and is sensitive to the size
and packing of dense subcellular components (such as the
nucleus, nucleolus, and mitochondria) as well as absorp-
tion by haemoglobin [139-142].
Müller et al. used three spectroscopic techniques to as-
sess 91 tissue sites from 15 patients with varying degrees
of oral malignancy (normal, dysplastic, and cancerous
sites) and eight healthy volunteers. By fitting a linear com-
bination of collagen and the reduced form of NADH
fluorescence spectra to intrinsic tissue fluorescence spec-
tra that had been excited by 337 nm and 358 nm laser
light, these researchers obtained direct biochemical infor-
mation regarding oral tissue native fluorophores with au-
tofluorescence spectroscopy. They measured wavelength-
dependent absorption and scattering coefficients by diffuse
reflectance spectroscopy to provide information regarding
tissue absorption and structure, such as haemoglobin con-
centration and stroma density. They then obtained light
ESS information resulting from single backscattering from
epithelial cell nuclei by subtracting the diffusely reflected
component from the measured reflectance; this provided
information concerning the size distribution of cell nuclei.
They described this method as trimodal spectroscopy and
reported a sensitivity and specificity of 96% and 96%, re-
spectively, in distinguishing cancerous/dysplastic (mild,
moderate, and severe) from normal tissue. In addition, the
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tissue with a sensitivity of 64% and a specificity of 90%
[139].
Lovat et al. studied ESS measurements collected in vivo
and matched them with pathologic findings of histological
specimens taken from identical sites within Barrett
oesophagus. They examined 181 matched biopsy sites
from 81 patients. ESS detected high risk sites with 92%
sensitivity and 60% specificity and differentiated high risk
sites from inflammation with sensitivity and specificity of
79% [142]. Sharwani et al. compared findings of ESS with
histopathology of oral tissues to ascertain whether this
technique could be used as an adjunct or alternative to
histopathology for identifying dysplasia. Twenty-five oral
sites from 25 patients who presented with oral leukoplakia
were examined by ESS using a pulsed xenon-arc lamp and
surgical biopsies acquired from each of the examination
sites. The results of the acquired spectra were then com-
pared with histopathology. Two sets of spectra were
obtained and linear discriminant analysis showed a sensi-
tivity of 72% and a specificity of 75% [143]. Canpolat et al.
used elastic light single-scattering spectroscopy to diag-
nose and demarcate skin malignancy. They performed
measurements on 28 lesions in 23 patients and reported
that this technique discriminated between malignant and
benign lesions with a sensitivity and specificity of 87% and
85%, respectively. Sensitivity and specificity of the system
for detecting positive surgical margins on 14 excised bi-
opsy samples were 80% and 90%, respectively [144]. Upile
et al. concluded that ESS is a promising means of distin-
guishing between normal, benign, and malignant skin
conditions [145]. In 2012, Qi et al. created multispectral
imaging in a rigid endoscope based on ESS [146]. A’Amar
et al. used ESS in diagnosis of prostate cancer; the re-
ported sensitivity was 83% and specificity 87% [147]. ESS
has also been used in diagnosis of cervical precancerous
lesion with a reported sensitivity of 87.5% [148].
Differential path-length spectroscopy
Differential path-length spectroscopy, a recently devel-
oped fibreoptic point measurement technique, measures
scattered photons that have travelled in predetermined
path lengths. Differential path-length spectroscopy is
considered to be a form of ESS that has fixed photon
path length, fixed photon visitation depth, and absolute
measurement of absorbers. This technology was devel-
oped at the Erasmus Medical Centre, Rotterdam, the
Netherlands [149,150]. The system uses a fibre-based
diffuse reflection spectrometer with a tungsten-halogen
lamp as a white light source. The first spectrometer uses
a bifurcated fibre for illumination and collection. A sec-
ond fibre carries diffusely reflected light to a second
spectrometer. The wavelength scales of the spectra re-
corded by each spectrometer are slightly different.Subtraction of the two measurements selects superficially
scattered light [150]. This spectrum is analysed mathemat-
ically and translated into a set of parameters that are related
to the microvasculature and intracellular morphology. The
signals give information about cell biochemistry, intracellu-
lar morphology and microvascular properties such as oxy-
gen saturation and average vessel diameter. The reported
sensitivity is 69% and specificity 85% [151]. Amelink et al.
used differential path-length spectroscopy to study 76 spec-
tra (45 nondysplastic and 31 dysplastic) collected from 27
leukoplakias. Based on a combination of the three variables
of blood oxygenation, vessel diameter, and blood volume
fraction, nondysplastic and dysplastic leukoplakias can be
discriminated with a sensitivity and specificity of 91% and
80%, respectively [152].
Optical tomography
This technology uses light scattering either to construct
an image, as in OCT, or to measure the average size of
different cell structures, thus providing objective infor-
mation about degree of dysplasia, as in angle-resolved
low coherence interferometry (a/LCI).
Optical coherence tomography
This is analogous to ultrasound imaging except that it
uses light rather than sound. The high spatial resolution
of OCT enables noninvasive in vivo “optical biopsy” and
provides immediate and localised diagnostic information.
The recent development of a Fourier domain mode lock
swept source-based OCT system has helped to simultan-
eously achieve a high speed (>100 kHz A-scan rate) and
good spatial resolution (<4 μm). In addition, the develop-
ment of various miniature scanning probes that provide
high-speed three-dimensional OCT pictures has been re-
ported [104-106,153-161]. Wilders-Smith et al. used OCT
to image suspicious oral lesions in 50 patients. After im-
aging, standard biopsy and histopathology were performed.
Two investigators who were blinded to OCT and histo-
pathology subsequently diagnosed the lesions. For detect-
ing carcinoma in situ or SCC versus non-cancer, sensitivity
was 93% and specificity was 93%; for detecting SCC versus
all other pathologies, sensitivity was 93% and specificity
was 97% [162,163]. Jerjes et al. compared findings of
OCT with histopathological diagnoses of suspicious
oral lesions to assess the feasibility of using OCT to
identify malignant tissue. Thirty-four oral lesions from
27 patients were assessed with swept-source frequency-
domain OCT. Four variables were assessed (changes in
keratin, epithelial, and subepithelial layers, and identifi-
cation of the basement membrane). These researchers
confirmed the feasibility of using OCT to identify
architectural changes in malignant tissues [164]. Olivo
et al. reported strong agreement between OCT-based
and histopathological diagnoses with sensitivity and
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et al. evaluated the capability of OCT to differentiate pre-
malignant and early malignant lesions of the upper aerodi-
gestive tract. In an unblinded evaluation, noninvasive and
invasive lesions were distinguished with a sensitivity of
88.9% and specificity of 89.0% whereas blinded evaluations
led had sensitivities of 100%, 66.7%, and 77.8% and speci-
ficities of 75.8%, 71.4%, and 70.3% [166]. In 2014, Pande
et al. studied the automated classification of OCT images
for the diagnosis of oral malignancy in the hamster cheek
pouch and reported the sensitivity and specificity of distin-
guishing malignant lesions from benign lesions were
90.2% and 76.3%, respectively [167]. They thus demon-
strated the feasibility of using quantitative image analysis
algorithms to extract morphological features from OCT
images to perform automated diagnoses of oral malignan-
cies in a hamster cheek pouch model [167]. The incorpor-
ation of OCT in specific tools, like handheld and catheter-
based probes, will further improve the implementation of
this technology in daily clinical practice [168,169].
Angle-resolved low coherence interferometry
A/LCI, an emerging biomedical imaging technology that
uses the properties of scattered light to measure the
average size of different cell structures, including cell
nuclei, directly measures diagnostically relevant subcel-
lular features of epithelial tissues up to 500 μm below
the surface. Unlike OCT, which is a subjective method
because it requires image interpretation, a/LCI performs
an objective analysis of tissue and delivers direct con-
firmation of precancerous disease to the physician
[104-106]. Wax et al. compared the average diameter
and texture of cell nuclei in rat oesophagus epithelial tis-
sue with grading criteria established in a previous a/LCI
study to prospectively grade neoplastic progression.
Overall, the combined studies showed 91% sensitivity
and 97% specificity for detecting dysplasia, using histo-
pathology as the standard [170]. Chalut et al. reported
that the a/LCI technique distinguishes normal from dis-
eased tissue with a sensitivity of 78% (7/9) and a specifi-
city of 91% (10/11) [171]. Terry et al. evaluated the
ability of a/LCI to identify dysplasia by studying tissues
from 27 patients undergoing partial colonic resection
surgery. They reported that a/LCI was able to separate
dysplastic from healthy tissues with a sensitivity of 92.9%
(13/14), a specificity of 83.6% (56/67), and an overall ac-
curacy of 85.2% (69/81) [172]. Zhu et al. studied 46 pa-
tients with Barrett oesophagus and reported that a/LCI
was able to detect dysplasia with 100% sensitivity and 84%
specificity [173]. Wax et al. have developed a novel spec-
troscopic technique for diagnosing disease at the cellular
level based on using low-coherence interferometry to de-
tect the angular distribution of scattered light. A/LCI
combines the ability of low-coherence interferometry toisolate scattering from subsurface tissue layers with the
ability of light scattering spectroscopy to obtain structural
information on subwavelength scales. The technology
shows promise as a clinical tool for in situ detection of
dysplastic or precancerous tissue [174]. Wax et al. and
Terry et al. reported sensitivity of this technology in diag-
nosis of oesophageal lesions of 100% and specificity 85%
[175,176].
Nuclear magnetic resonance spectroscopy (NMR)
NMR exploits the magnetic properties of certain atomic
nuclei to determine the physical and chemical properties
of atoms or the molecules in which they are contained.
It relies on the phenomenon of nuclear magnetic reson-
ance and can provide detailed information about the
structure, dynamics, reaction state, and chemical envir-
onment of molecules. This technology allows three-
dimensional study of atoms in molecules; the larger the
magnet, the more sensitive the device. Using NMR, it is
possible to view how protein links with DNA [104-106].
NMR has been used to identify metabolic signatures of
OSCC compared with normal tissues [177,178]. Clinical
studies have confirmed that the choline/creatine ratio is
significantly higher in OSCC than in normal tissue
[179,180]. An NMR study of ex vivo tumour tissue
found higher concentrations of taurine, choline, glutamic
acid, lactic acid, and lipids in SCC than in normal tissue
[181]. In addition, overexpression of glucose trans-
porters, especially of glucose transporter 1, which is as-
sociated with increased glycolytic metabolism, has been
reported in OSCC [178]. Other authors who have exam-
ined the role of advanced glycated end-products and in-
creased numbers of their receptors in patients with
primary gingival carcinoma have shown that expression
of these receptors correlates closely with the invasive-
ness of OSCC [182,183].
Infrared spectroscopy
This distinguishes different biomolecules by probing
chemical bond vibrations and using these molecular and
submolecular patterns to define and differentiate patho-
logical from normal tissues [184,185]. Optical Biopsy
technologies have been summarized in (Table 6).
Discussion
Patients with potentially malignant oral lesions referred
to specialist centres are faced with long waiting times,
leading to significant diagnostic delays [186]. In the
United States, the mean time from detection of a poten-
tially malignant lesion by a primary healthcare provider
to an appointment with a specialist for evaluation is re-
portedly 35.9 days [16]. In some cases, this delay exceeds
10 months [15]. In Canada, the diagnosis of oral cancer
is delayed by 4.5 weeks, which is significantly shorter
Table 6 Optical biopsy
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portedly 18.4 weeks [15-17]. This longer delay is attrib-
uted to the disparity in healthcare systems and health
insurance-related issues in the United States [15]. Delays
in diagnosis of oral cancer by as little as 1 month may
contribute to a diagnosis of later stage disease [17].
Moreover, treatment delays of more than 40 days in pa-
tients with early-stage oral cancer are associated with an
increased risk of locoregional failure, which affects
survival [18]. In addition, surgical biopsies are time-
consuming, uncomfortable, and stressful for the patient
and are relatively expensive procedures. Therefore, de-
velopment of acceptable noninvasive diagnostic methods
that can discriminate benign oral lesions from OSCC
and its precursors with minimal false-positive and false-
negative results would be beneficial not only for patients
but also for society; this would reduce healthcare costs
through avoiding unnecessary surgical biopsies and min-
imise long waiting times for diagnosis at specialist cen-
tres [15-18].
TB is one of the oldest noninvasive methods for diag-
nosing OSCC. Being highly sensitive and moderately
specific for malignant lesions, it can be used for screen-
ing and to rule out suspicious areas. However, it is an
unreliable technique because it is highly subjective and
depends on the experience of the investigator. Unlike
sampling of uterine cervix cells, analysis of surface epi-
thelial cells of the oral cavity and oropharynx by stand-
ard exfoliative cytology (brush biopsy) has proven to be
unreliable, identifying as few as 31% of dysplastic tissues
[26]. Computerised analysis of oral brush biopsy speci-
mens within the context of premalignant lesions report-
edly has a positive predictive value of 58.3%, and with
the support of molecular markers including tenascin and
cytokeratins, accurate diagnoses are achievable [25].
Exfoliative cytology based on a nanobiochip sensor
platform for oral cancer detection has been described.
The diagnosis of oral carcinoma by oral brush biopsy
with exfoliative cytology based on nanobiochip sensor
platform has 97–100% sensitivity and 86% specificity
[25,186,187]. Currently, the only commercially available
diagnostic adjunct employing exfoliative cytology is the
OralCDx® Brush Test with computer-assisted analysis
from OralScan Laboratories. In a large multi-centre study,
the OralCDx® test demonstrated high sensitivity and speci-
ficity (100% and 93%, respectively) for detection of atypical
oral epithelia based on morphology, keratinisation, and
ploidy patterns [25,187]. The OralCDx® Brush Biopsy (or
BrushTest® as it is marketed to dentists) is an in-office test
to help ensure that seemingly harmless white or red spots
in patient’s mouths are not precancerous or cancerous.
OralCDx® has two components: (i) a specially designed
brush that is used to painlessly obtain a sample of an oral
lesion; and (ii) highly sophisticated computers in aspecialty laboratory where specially-trained pathologists
analyse the sample and provide a result. In contrast to a
typical cytologic smear, such as a Pap smear, which sam-
ples cells only from the superficial layer, the OralCDx®
brush obtains a complete transepithelial biopsy specimen,
collecting cells from all three layers (superficial, intermedi-
ate and basal) of the epithelium. OralCDx® requires no an-
aesthesia and causes no pain and minimal or no bleeding.
This technique is very accurate and has been the subject
of well-controlled, randomised, clinical trials. In every
study in which the same lesion was assessed by both an
OralCDx® brush and scalpel biopsy, OralCDx® was shown
to be at least as sensitive as scalpel biopsy in identifying
dysplasia or cancer. In addition, the positive and negative
predictive values of OralCDx® have been repeatedly shown
in published studies to be substantially greater than those
of other accepted life-saving tests such as the Pap smear,
mammogram, and prostate-specific antigen [25,187].
A point of care device for testing saliva to detect oral
cancer that is not yet commercially available has been
developed by the University of California, Los Angeles
(UCLA) Collaborative Oral Fluid Diagnostic Research
Laboratory, led by Dr David Wong [188,189]. The test,
known as the oral fluid nanosensor test (OFNASET), is
a point of care, automated, and easy-to-use integrated
system that uses electrochemical detection of salivary
proteins and nucleic acids and can measure up to eight
different biomarkers in a single test in less than 15 mi-
nutes [188,189]. The OFNASET screens for the risk of
oral cancer, allowing only test-positive patients to be re-
ferred for biopsies [188,189]. It is expected to detect oral
cancer at an earlier stage than other techniques, when
treatment is more effective and less costly. In addition to
detecting oral cancer, the OFNASET will be able to as-
sess for pancreatic, breast, and lung cancers, Sjögren
syndrome, Alzheimer disease, and type II diabetes. The
developers of this system anticipate obtaining FDA ap-
proval for salivary biomarkers of diseases by approxi-
mately 2016 to 2017, at which time OFNASET will
become commercially available [188,189].
Most optical biopsy technologies are still in experimen-
tal studies and clinical trials. The FDA, Health Canada,
and the World Health Organization have approved VEL-
scope® (LED Dental) for direct visualisation of autofluores-
cence of oral cavity and diagnosis of oral carcinoma
[190,191]. The VELscope® system now has expanded indi-
cations for use based on recently published clinical data in
peer-reviewed publications. These indications are as fol-
lows [190,191]: (i) to help detect oral cancer and dysplasia;
(ii) to help detect mucosal abnormalities that may not be
visible or apparent to the naked eye; and (iii) as an aid to
identifying diseased tissue around a clinically apparent le-
sion to help determine the appropriate margin for surgical
excision. The VELscope® Vx system is an adjunctive
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a supplement to traditional intra- and extra-oral head and
neck examination. Unlike other adjunctive devices used
for oral examinations, the VELscope® Vx does not require
any dyes or prolonged testing procedures. In fact, a VEL-
scope® Vx exam can be performed in the dentist’s office
during a routine hygiene exam in about 2 minutes
[190,191]. In a study of 122 oral mucosa biopsies from 20
patients, Poh et al. showed that VELscope® imaging can
identify oral neoplasia in the operating room setting with
a sensitivity of 97% and specificity of 94% [99].
A/LCI technology is unique in being able to evaluate
microstructure in epithelial tissues up to 500 μm below
the surface. The technique uses real-time analysis of
light scattered from tissues to detect enlargement of nu-
clei and other organelle-related changes indicative of
early cancer progression. This is an alternative to OCT,
which aims to construct a high-resolution image that is
analysed either by a trained expert or computer algo-
rithm to provide diagnostic information. In contrast, a/
LCI measures diagnostically relevant variables directly
and provide them to the physician to enable faster, more
direct confirmation of precancerous disease. To date,
the technique has been shown to accurately detect pre-
cancer in the oesophagus, colon, oral cavity and cervix.
Oncoscope (Durham, NC, USA) is now developing a/
LCI commercially. In the United States, FDA approval
for this application of Oncoscope’s system is expected in
2016 [190,191].
Saliva-based oral cancer diagnosis and optical biopsy
are promising noninvasive methods for diagnosing
OSCC with high sensitivity and reliable specificity that
are easy for primary care practitioners to perform clinic-
ally. These technologies provide objective information
and do not require special experience for interpretation
of the information obtained. They could be widely used
in the near future as reliable routine modalities for oral
cancer diagnosis and evaluation of the degree of dyspla-
sia of pre-cancerous lesions. It is clearly evident that
screening and early detection of cancer and its precur-
sors have the potential to reduce the morbidity and mor-
tality of this disease. These technologies may change the
consequences of this disease in the near future.Conclusions
It is clear that screening for and early detection of cancer
and pre-cancerous lesions have the potential to reduce the
morbidity and mortality of this disease. Advances in tech-
nologies for saliva-based oral diagnosis and optical biopsy
are promising pathways for the future development of
more effective noninvasive methods for diagnosing OSCC
that are easy to perform clinically in primary care settings.Competing interests
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